Related Experiment Videos
A patient with apolipoprotein E2 variant (Q187E) without lipoprotein glomerulopathy
Mikito Hayakawa1, Minoru Okubo, Hideyuki Katori
1Department of Endocrinology and Metabolism, Kidney Center, Toranomon Hospital, Tokyo, Japan.
Summary
Not all apolipoprotein E variants cause lipoprotein glomerulopathy (LPG). The specific mutation location, like in apo E Toranomon (Q187E), influences LPG development, with diabetic nephrosclerosis observed in this case.
Area of Science:
- Nephrology
- Genetics
- Cardiovascular Medicine
Background:
- Apolipoprotein E (apo E) variants are linked to lipoprotein glomerulopathy (LPG), a condition causing type III hyperlipoproteinemia (type III HLP), proteinuria, and nephrotic syndrome.
- Understanding the specific role of apo E variants in LPG pathogenesis is crucial for diagnosis and treatment.
Observation:
- A patient with type III HLP and the apo E Toranomon variant (Q187E) presented with type 2 diabetes mellitus.
- Kidney biopsy revealed diabetic nephrosclerosis, with no evidence of lipoprotein thrombi characteristic of LPG.
Findings:
- The apo E Toranomon variant (Q187E) did not result in LPG in this patient, despite the presence of type III HLP.
- Histologic findings were consistent with diabetic nephrosclerosis, suggesting alternative kidney pathology.
Implications:
- This case highlights that not all apo E variants precipitate LPG, underscoring the importance of mutation location.
- The specific genetic alterations in apo E are critical determinants for the development of lipoprotein glomerulopathy.